Reference(s)
Click here to return to the Reference Table

Cancer type: Cholangiocarcinoma


HGF/SF expression

Reference Number: 470
Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, Sobhon P. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 136, 78-84 (2006)
PubMed link      E-mail link

Reference Number: 850
Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 10, 302 (2010)
PubMed link      E-mail link

Reference Number: 851
Menakongka A, Suthiphongchai T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol. 16, 713-22 (2010)
PubMed link      E-mail link

Reference Number: 852
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE. Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol. 51, 77-92 (2009)
PubMed link      E-mail link

Reference Number: 1405
Ge X1, Wang Y, Li Q, Yu H, Ji G, Miao L. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol Rep. 30, 448-54 (2013)
PubMed link      E-mail link

Met expression

Reference Number: 305
Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40, 269-78 (2002)
PubMed link      E-mail link

Reference Number: 470
Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, Sobhon P. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 136, 78-84 (2006)
PubMed link      E-mail link

Reference Number: 473
Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 66, 6622-7 (2006)
PubMed link      E-mail link

Reference Number: 1121
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 105, 131-8 (2011)
PubMed link      E-mail link

Reference Number: 1244
Dai R, Li J, Fu J, Chen Y, Wang R, Zhao X, Luo T, Zhu J, Ren Y, Cao J, Qian Y, Li N, Wang H. The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem. 287, 39812-23 (2012)
PubMed link      E-mail link

Reference Number: 1405
Ge X1, Wang Y, Li Q, Yu H, Ji G, Miao L. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol Rep. 30, 448-54 (2013)
PubMed link      E-mail link

Reference Number: 1895
Watanabe H, Yokoyama Y, Kokuryo T, Ebata T, Igami T, Sugawara G, Mizuno T, Shimoyama Y, Nagino M. Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma. Ann Surg Oncol. 22, 2235-42 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 1121
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 105, 131-8 (2011)
PubMed link      E-mail link

Reference Number: 1782
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One. 9, e100586 (2014)
PubMed link      E-mail link

Mutation of Met

In vitro studies

Reference Number: 402
Imai Y, Kubota Y, Yamamoto S, Tsuji K, Shimatani M, Shibatani N, Takamido S, Matsushita M, Okazaki K. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol. 20, 287-93 (2005)
PubMed link      E-mail link

Reference Number: 456
Pongchairerk U, Guan JL, Leardkamolkarn V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1. World J Gastroenterol. 11, 5845-52 (2005)
PubMed link      E-mail link

Reference Number: 470
Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, Sobhon P. Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res. 136, 78-84 (2006)
PubMed link      E-mail link

Animal models

Reference Number: 30
Radaeva, S., Ferreira-Gonzalez, A. & Sirica, A. E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29, 1453-62. (1999).
PubMed link      E-mail link

Therapeutic Development

Reference Number: 671
Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14, 2990-4 (2008)
PubMed link      E-mail link

Reference Number: 1315
Ge X, Wang Y, Wang Y, Li Q, Yu H, Miao L. NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells. Dig Dis Sci. 58, 1636-43 (2013)
PubMed link      E-mail link

Reference Number: 1405
Ge X1, Wang Y, Li Q, Yu H, Ji G, Miao L. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol Rep. 30, 448-54 (2013)
PubMed link      E-mail link

Reviews

Reference Number: 760
Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14, 2990-4 (2008)
PubMed link      E-mail link

Reference Number: 774
Kuroki T, Tajima Y, Kanematsu T Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J Hepatobiliary Pancreat Surg. 12, 463-6 (2005)
PubMed link      E-mail link